<DOC>
	<DOCNO>NCT02062502</DOCNO>
	<brief_summary>This study evaluate immunogenicity , safety , tolerability VARIVAX™ ( Varicella Virus Vaccine Live ) manufacture New Seed Process ( NSP ) compare VARIVAX™ 2007 process . The primary hypothesis test antibody response rate mean antibody titer induce 6 week single vaccination VARIVAX™ NSP non-inferior induce VARIVAX™ 2007 process , antibody response rate induce VARIVAX™ NSP acceptable .</brief_summary>
	<brief_title>Evaluation Immunogenicity Safety VARIVAX™ New Seed Process ( NSP ) Children ( V210-063 )</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Negative clinical history varicella , herpes zoster , measles , mumps , rubella Received measles , mumps , rubella , varicella vaccine time prior study , anticipate receive vaccine outside study Any congenital acquire immune deficiency , neoplastic disease , depressed immunity Received systemic immunomodulatory steroid within 3 month prior enter study expect receive course study History allergy anaphylactic reaction neomycin , gelatin , sorbitol , egg protein , chicken protein , component VARIVAX™ MMR II™ Received salicylates within 14 day prior study vaccination Exposed varicella , herpes zoster , measles , mumps , rubella 4 week prior study vaccination Received immune globulin , blood transfusion , bloodderived product within 5 month prior study vaccination History seizure disorder , include febrile seizure Fever illness ( &gt; =102.2 °F [ 39.0 °C ] within 72 hour prior study vaccination History thrombocytopenia Born human immunodeficiency virus ( HIV ) infect mother Participated clinical trial ( surveillance study ) within 30 day prior study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>